ALPS Advisors
ALNY icon

ALPS Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

ALPS Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$360K Sell
1,457
-85
-6% -$21.6K ﹤0.01% 1054
2026
Q2 		$464K Buy
+1,542
New +$465K ﹤0.01% 1009
2017
Q2 		– Sell
-73,998
Closed -$3.79M – 769
2017
Q1 		$3.79M Sell
73,998
-8,470
-10% -$391K 0.03% 151
2016
Q4 		$3.09M Buy
+82,468
New +$3.45M 0.02% 155

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ALPS Advisors's ALNY Position: Q3 2026 in Review

ALPS Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.5% in Q3 2026, selling an estimated $21.6K and leaving 1,457 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #1054.

ALPS Advisors first reported a position in ALNY in Q4 2016 and has held it in 4 quarters since. The position peaked at $3.79M in Q1 2017. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • ALPS Advisors held 1,457 shares of Alnylam Pharmaceuticals worth $360K as of Q3 2026.
  • ALPS Advisors sold 85 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $21.6K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #1054 holding.
  • ALPS Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 4 quarters since.
  • ALPS Advisors's Alnylam Pharmaceuticals position peaked at $3.79M in Q1 2017.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.